| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 14,750 | 620 | 240 | 930 | 110 |
| Sales Growth | +2,279.03% | +158.33% | -74.19% | +745.46% | +175.00% |
| Net Income | -413,560 | -583,200 | -416,570 | -346,790 | -92,380 |
| Net Income Growth | +29.09% | -40.00% | -20.12% | -275.40% | -40.42% |
Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest Inc., is based in CULVER CITY, Calif.
Fiscal Year End Date: 12/31